An FDA-Approved Obesity Medications Guide

By GOAL.MD Team — November 16, 2026

This FDA-approved obesity medications guide explains who may qualify, how GLP-1 options work, and what physician-supervised care should include safely.

Weight loss medication is not a shortcut around health. For eligible adults, it is a clinically validated tool that can address the biological drivers of obesity, including appetite signaling, hunger, and metabolic regulation. This FDA-approved obesity medications guide clarifies the options, the qualifications, and the level of medical oversight that should come with treatment.

The right medication is never simply the one generating the most headlines. It is the option that fits your health history, goals, current medications, tolerance for side effects, and long-term plan. A physician-supervised approach helps make that decision with precision.

What FDA-Approved Obesity Medications Treat

Obesity is a chronic medical condition, not a failure of discipline. The FDA has approved several prescription medications to help adults manage weight alongside nutrition, physical activity, sleep, and other lifestyle measures. These therapies are intended to support sustained progress, not replace the foundations that protect long-term health.

Most medications are considered for adults with a body mass index, or BMI, of 30 or higher. Adults with a BMI of 27 or higher may also qualify when they have a weight-related condition such as high blood pressure, dyslipidemia, obstructive sleep apnea, prediabetes, or type 2 diabetes. A clinician looks beyond BMI alone, since your medical history and risk profile matter.

FDA approval also has a specific meaning. It means a medication has been reviewed for safety and effectiveness for a defined use. It does not mean every person is a candidate, nor does it guarantee the same result for every patient.

The Main FDA-Approved Medication Options

GLP-1 and dual-action medications

GLP-1-based medications have changed the conversation around medical weight management because they work with pathways involved in appetite and satiety. Semaglutide, sold for chronic weight management under the brand name Wegovy, is a once-weekly medication that mimics a naturally occurring gut hormone called GLP-1. It can help people feel full sooner, stay full longer, and reduce food noise.

Tirzepatide, sold for chronic weight management as Zepbound, acts on both GIP and GLP-1 receptors. This dual activity can support meaningful weight reduction for appropriate patients. Like semaglutide, it is administered weekly and is part of a broader, physician-guided plan.

Liraglutide, sold as Saxenda for chronic weight management, is also a GLP-1 receptor agonist. It is taken daily rather than weekly. For some patients, that schedule or their individual response may make it a reasonable option.

GLP-1 and dual-action therapies are often associated with gastrointestinal side effects, particularly nausea, constipation, diarrhea, vomiting, or abdominal discomfort. Clinicians commonly use a gradual dose-escalation schedule to improve tolerability. Slower titration, hydration, protein intake, and timely communication about symptoms can make a substantial difference.

Other prescription weight-loss medications

Not every patient needs or can use a GLP-1-based treatment. FDA-approved options also include Qsymia, a combination of phentermine and topiramate; Contrave, a combination of naltrexone and bupropion; and Xenical, the prescription form of orlistat. Each works differently, with its own expected benefits, limitations, and safety considerations.

Qsymia may not be appropriate for people with certain cardiovascular concerns, glaucoma, hyperthyroidism, or pregnancy. Contrave may be unsuitable for those with uncontrolled hypertension, seizure disorders, opioid use, or certain psychiatric histories. Orlistat reduces dietary fat absorption, which can lead to gastrointestinal effects and requires attention to vitamin intake.

Phentermine is FDA-approved for short-term weight management, rather than chronic use. Imcivree is approved for certain rare genetic causes of obesity and is not a general weight-loss medication. These distinctions are why a personalized clinical review matters more than a one-size-fits-all recommendation.

What Is Not the Same as an Obesity Approval

Some medications are FDA-approved for type 2 diabetes but not specifically approved for chronic weight management. Ozempic and Mounjaro, for example, contain the same active ingredients as Wegovy and Zepbound, respectively, but they have different FDA-approved indications and labeling.

That distinction matters. A clinician may consider the complete medical picture when selecting treatment, but patients should understand whether a medication is being used for its FDA-approved obesity indication or for another approved condition.

Compounded products require equal care. A compounded medication is not FDA-approved, and it does not undergo the same FDA review as an approved branded drug. Compounding may be considered in limited circumstances by a licensed clinician and pharmacy, but it should not be confused with an FDA-approved therapy. Be cautious with online offers that promise prescription medication without a real clinical evaluation, clear sourcing, or ongoing supervision.

Who Should Avoid or Carefully Review Treatment

A thorough screening process protects both results and safety. GLP-1-based medications are generally not recommended for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. They also require careful assessment for a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, kidney concerns, and diabetes medications that may affect blood sugar.

Pregnancy and plans for pregnancy should always be part of the conversation. Weight-loss medications are not used during pregnancy, and patients should discuss appropriate timing and contraception with their prescribing clinician.

Medication selection also depends on what you already take. Blood pressure medications, diabetes treatments, opioids, antidepressants, and stimulants can all influence which option is appropriate. A responsible telehealth program asks these questions before prescribing, not after an order is placed.

What Physician-Supervised Care Should Look Like

Convenient care should not mean reduced clinical standards. A high-quality telehealth program begins with a detailed health intake and clinician review. Depending on your history, this may include recent lab work, blood pressure data, medication reconciliation, and screening for contraindications.

Once treatment begins, follow-up is essential. Your care plan should account for dose adjustments, side-effect management, changes in appetite, progress toward health goals, and the possibility that a different medication may be a better fit. Weight alone is not the only outcome worth tracking. Waist circumference, blood pressure, energy, mobility, sleep, and metabolic markers can offer a more complete view of progress.

At GOAL.MD, physician-supervised programs are designed to pair personalized treatment planning with the practical advantage of telehealth and medication delivered to your door. That model can make consistent care more attainable for busy adults, while preserving the clinical review that prescription therapy requires.

Setting Expectations for Sustainable Results

Medication can create momentum, but sustainable weight management still requires a plan for the life around it. The strongest programs help patients build meals around adequate protein and fiber, protect lean muscle with resistance training where appropriate, prioritize sleep, and develop routines that can hold up during travel, work demands, and social events.

Progress is rarely perfectly linear. Some people lose weight quickly at first, while others respond more gradually. Plateaus can occur even when a treatment is working. Your clinician may adjust the dose, reassess adherence and tolerability, review other health factors, or determine whether a different approach makes more sense.

It is also reasonable to ask what happens if medication is stopped. Appetite and weight can return when treatment ends, especially without a durable maintenance strategy. For many people, obesity medication is a long-term therapy, much like medication used to manage other chronic conditions. The duration should be individualized, based on benefits, risks, preferences, and ongoing clinical response.

The best next step is not choosing a medication from a headline. It is choosing a qualified clinician who can evaluate your health, set realistic targets, and help you pursue measurable progress with safety at the center of the plan.

Medically reviewed by Dr. Michael Mimlitz, MD (NPI 1508891870), Chief Physician of GOAL.MD. Physician-supervised telehealth. More at goal.md/blog.